Benefit-risk assessment of treatments for heparin-induced thrombocytopenia

Drug Safety

Volumn 26, Issue 9, 2003, Pages 625-641

  Messmore, Harry L ^a,b   Jeske, Walter P ^b   Wehrmacher, William H ^b   Walenga, Jeanine M ^b  

^a HINES VA HOSPITAL   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; ARGATROBAN; DANAPAROID; DEXTRAN; DEXTRAN 40; DEXTRAN 70; DRUG ANTIBODY; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HIRULOG; IMMUNOGLOBULIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN INHIBITOR; UROKINASE; WARFARIN;

ANAPHYLAXIS; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SAFETY; FETOTOXICITY; GANGRENE; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARINIZATION; HUMAN; PLASMAPHERESIS; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN NECROSIS; THROMBECTOMY; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS;

EID: 0038442147     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200326090-00003     Document Type: Review

References (112)

1. Lee DH, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia. 2nd rev. ed. New York: Marcel Dekker, 2001: 87-121
2. Powers PJ, Cuthbert D, Hirsh J. Thrombocytopenia found uncommonly during heparin therapy. JAMA 1979; 241: 2396-7
3. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5
4. Weismann RE, Tobin RW. Arterial embolism occurring systemic heparin therapy. Arch Surg 1958; 76: 219-27
5. Roberts B, Rosato FE, Rosato EF. Heparin - a cause of arterial emboli? Surgery 1964; 55: 803-8
6. Natelson EA, Lynch EC, Alfrey CP, et al. Heparin-induced thrombocytopenia. Ann Intern Med 1969; 71: 1121-5
7. Bell WR, Tomasulo PA, Alving BM, et al. Thrombocytopenia occurring during the administration of heparin. A prospective study in 52 patients. Ann Intern Med 1976; 85: 155-60
8. Israels ED, Nisli D, Paraskevas F, et al. Platelet Fc receptor as a mechanism for Ag-Ab complex induced platelet injury. Thromb Diath Haemorrh 1973; 29: 434-8
9. Chong BH, Grace CS, Rozenberg MC. Heparin-induced thrombocytopenia: effect of heparin platelet antibody on platelets. Br J Haematol 1981; 49: 531-6
10. Messmore HL, Fareed J, Parvez Z, et al. Studies on the mechanism of heparin-induced thrombocytopenia. Thromb Haemost 1981; 46: 215
11. Kelton JG, Sheridan D, Brain H, et al. Clinical usefulness of testing for a heparin-dependent platelet aggregating factor in patients with suspected heparin associated thrombocytopenia. J Lab Clin Med 1984; 103: 606-12
12. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia [letter]. Thromb Haemost 1992; 68: 95
13. Visentin GP, Ford SE, Scott JP, et al. Antibodies from patients with heparin-induced thrombocytopenia are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81-8
14. Amiral J, Wolf F, Fisher AM, et al. Pathogenicity of IgA and/or IgM antibodies to heparin PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 1996; 92: 954-9
15. Denomme GA, Warkentin TE, Horsewood P, et al. Activation of platelets by sera containing IgG, heparin dependent antibodies: an explanation for the predominance of the FcγRIIa "low responder" (his 131) gene in patients with heparin-induced thrombocytopenia. J Lab Clin Med 1997; 130: 278-84
16. Amiral J, Marfaing-Koka A, Wolf M, et al. Presence of auto-antibodies to interleukin-8 or neutrophile-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 1996; 88: 410-6
17. Pouplard C, Lochmann S, Renard B, et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 2001; 97 (10): 3300-2
18. Jeske WP, Schlenker R, Bakhos M, et al. Are leukocytes important for platelet activation in heparin-induced thrombocytopenia? Ann Hematol 2000; 79 Suppl. 1: A46
19. Fareed J, Walenga JM, Hoppensteadt DA, et al. Selectins in the HIT syndrome. Pathophysiologic role and therapeutic modulation. Semin Thromb Hemost 1999; 25 Suppl. 1: 37-42
20. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia, 2nd rev. ed. New York: Marcel Dekker, 2001: 43-86
21. Wehrmacher W, Messmore H. Thrombocytopenia and thrombosis due to heparin. Cardiovasc Rev Rep 1998 Apr: 38-48
22. Messmore H, Upadhyay G, Farid S, et al. Heparin-induced thrombocytopenia and thrombosis in cardiovascular surgery. In: Pifarré R, editor. New anticoagulants for the cardiovascular patient. Philadelphia (PA): Hanley & Belfus, 1997: 83-94
23. Wallis D, Lewis B, Messmore H, et al. Heparin-induced thrombocytopenia and thrombosis syndrome. Clin Appl Thromb Hemost 1998; 4: 160-3
24. Boshkov LK, Warkentin TE, Hayward CPM, et al. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 1993; 84: 322-8
25. Beland B, Busse H, Loick HM, et al. Phlegmasia cerulea dolens, cerebral venous thrombosis, and fatal pulmonary embolism due to heparin-induced thrombocytopenia syndrome. Anesth Analg 1997; 85: 1272-4
26. Kappa JR, Fisher CA, Berkowitz HD, et al. Heparin-induced platelet activation in sixteen surgical patients: diagnosis and management. J Vasc Surg 1987; 5: 101-9
27. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344: 1286-92
28. Hirsh J, Warkentin T, Shaughnessy S, et al. Heparin and low-molecular weight heparin. Mechanisms of action, pharmacokinetics, dosing monitoring, efficacy and safety. Consensus Conference on Antithrombotic Therapy. Chest 2001 Jan; 119 Suppl.: 64S-94S
29. Wallis DE, Lewis BE, Messmore HL, et al. Inadequacy of current prevention strategies for heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 1999; 5 Suppl. 1: 516-20
30. Walenga JM, Jeske W, Fasanella A, et al. Laboratory tests for the diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemost 1999; 25 Suppl. 1: 43-9
31. Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993; 69: 344-50
32. Schnell MK, Giordano KJ, Munezzo HM, et al. Diagnosis of heparin-induced thrombocytopenia (HIT): comparison of methods. Transfusion 1998; 38 Suppl.: 98S
33. Izban KF, Lietz HW, Hoppensteadt DA, et al. Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemost 1999; 25 Suppl. 1: 51-6
34. Walenga JM, Jeske WP, Wood JJ, et al. Laboratory tests for heparin-induced thrombocytopenia. Semin Hematol 1999; 36 (1 Suppl. 1): 22-8
35. Prechel M, Bano A, Drenth AF, et al. Assay selection and interpretation for laboratory testing of heparin-induced thrombocytopenia: diagnostic implications [abstract]. Blood 2001; 98 (11): 36a
36. Greinacher A, Warkentin TE. Treatment of heparin-induced thrombocytopenia: an overview. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia, 2nd rev. ed. New York: Marcel Dekker, 2001: 291-319
37. Pouplard C, Amiral J, Borg JY, et al. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Patrol 1999; 111 (5): 700-6
38. Greincher A, Eichler P, Lubenow N, et al. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parental treatment with lepirudin and its therapeutic aPTT range. Blood 2000; 96: 846-51
39. Chong BH, Gallus AS, Cade JF, et al. Prospective randomized open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis. Thromb Haemost 2001; 86: 1170-5
40. Farag SS, Savora H, O'Malley CJ, et al. Lack of in-vitro cross reactivity predicts safety of low-molecular weight heparins in heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 1997; 2: 58-62
41. Riess KFC, Lower C, Seelig C, et al. Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: successful for aortic valve replacement in man. J Thorac Cardiovascular Surg 1995; 110: 265-7
42. Matsuo T, Kario K, Chikahera Y, et al. Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor. Br J Haematol 1992; 82: 627-8
43. Mehta DP, Yoder EL, Appel J, et al. Heparin-induced thrombocytopenia and thrombosis: reversal with streptokinase: a case report and review of the literature. Am J Hematol 1991; 36: 275-9
44. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 1993; 70: 554-61
45. Ortel TL, Chong BH. New treatment options for heparin-induced thrombocytopenia. Semin Hematol 1998; 35: 26-34
46. Magnani H. Organon (danaparoid sodium) use in the syndrome of heparin-induced thrombocytopenia. Platelets 1997; 8: 74-81
47. Wilde MI, Markham A. Danaparoid: a review of it pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs 1997; 54 (6): 903-24
48. Walenga JM, Koza MJ, Lewis BE, et al. Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin Appl Thromb Hemost 1996; 2 Suppl. 1: S21-7
49. Chong BH, Ismail F, Cade J, et al. Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172. Blood 1989; 73 (6): 1592-6
50. Bauersachs RM, Lindhoff-Last E, Ehrly AM, et al. Treatment of hirudin overdosage in a patient with chronic renal failure. Thromb Haemost 1999; 81: 323-4
51. Koster A, Merkle F, Hansen R, et al. Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass: assessment of different filter systems. Anesth Analg 2000; 91: 265-9
52. Walenga JM, Ahmad S, Hoppensteadt D, et al. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb Res 2002; 105: 401-5
53. Lewis BE, Walenga JM, Hursting MJ. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Cardiovasc Rev Rep 2002; 23: 445-54, 457
54. McKeage K, Plosker GL. Argatroban. Drugs 2001; 61 (4): 515-522
55. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20: 318-29
56. Swan SK, St Peter JV, Lambrecht LJ, et al. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000; 20: 756-70
57. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103: 1838-43
58. Lewis BE, Wallis DE, Zehnder JL, et al. Argatroban reexposure in patients with heparin-induced thrombocytopenia [abstract]. Blood 2000; 96 Pt 1: 52a
59. Markwardt F. Hirudin: the promising antithrombotic. Cardiovasc Drug Rev 1992; 10: 211-32
60. Eichler P, Friesen HJ, Lubenow N, et al. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT and clinical relevance. Blood 2000; 96: 2373-8
61. Song X, Huhle G, Wang L, et al. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation 1999; 100 (14): 1528-32
62. Refludan (lepirudin) package insert. Berlex Laboratories. Wayne (NJ) USA
63. Greinacher A, Völpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999; 99: 73-80
64. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999; 100: 587-93
65. Farrier B, Eichler P, Kroll H, et al. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 2001; 85: 950-7
66. Pötzsch B, Madlener K, Seelig C, et al. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass - assessment of the whole blood ecarin clotting time. Thromb Haemost 1997; 77 (5): 920-5
67. Nurmohamed MT, Berckmans RJ, Morrien-Salomons WM, et al. Monitoring anticoagulant therapy by activated partial thromboplastin time: hirudin assessment. Thromb Haemost 1994; 72: 685-92
68. Walenga JM, Fasanella AR, Iqbal O, et al. Coagulation laboratory testing in patients treated with argatroban. Semin Thromb Hemost 1999; 25 Suppl. 1: 61-6
69. Sheth SB, DiCicco RA, Hursting MJ, et al. Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 2001; 85: 435-40
70. Walenga JM, Drenth AF, Mayuga M, et al. Effects of argatroban alone and combined with oral anticoagulation on coagulation parameters [abstract]. Blood 2002; 100 (11): 131b
71. Gossage JR. Early intervention in massive pulmonary embolism. Postgrad Med 2002; 111 (3): 27-50
72. Hyers T, Agnelli G, Huss R, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119: 176S-93S
73. Ohrman E, Harrington R, Carmen C, et al. Intravenous thrombolysis in acute myocardial infarction. Chest 2001; 119: 253S-77S
74. Qurnones-Baldrich WJ, Baker JD, Busuttil R, et al. Intraoperative infusion of lyric drug for thrombotic complications of revascularization. J Vasc Surg 1989; 10: 408-17
75. Marder VJ. Thrombolytic therapy 2001. Blood Rev 2001; 15: 143-57
76. Belkin M, Belkin B, Buckman C, et al. Intra-arterial thrombolytic therapy: efficacy of streptokinase vs. urokinase. Arch Surg 1986; 121: 769-73
77. Working Party on Thrombolysis in the Management of Limb Ischemia. Thrombolysis in the management of limb arterial occlusion: towards a consensus interim report. J Intern Med 1996; 240: 343-55
78. Working Party on Thrombolysis in the Management of Limb Ischemia. Thrombolysis in the management of lower limb peripheral arterial occlusion - a consensus document. Am J Cardiol 1998; 81: 207-18
79. Lewis BE, Ferguson JJ, Grassman ED, et al. Successful coronary interventions performed with argatroban anticoagulation in patients with heparin-induced thrombocytopenia and thrombosis syndrome. J Invas Cardiol 1996; 8: 410-7
80. Lewis BE, Matthai WH, Cohen M, et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Cathet Cardiovasc Intervent 2002; 57: 177-84
81. Pötzsch B, Klovekorn WP. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med 2000; 343 (7): 515-6
82. Olinger GN, Hussey CV, Olive JA, et al. Cardiopulmonary bypass for patients with previously documented heparin induced platelet aggregation. J Thorac Cardiovasc Surg 1984; 87: 673-7
83. Koster A, Kukucka M, Bach F, et al. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type li and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban. Anesthesiology 2001; 94: 245-51
84. Koster A, Hansen R, Kuppe H, et al. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: a 1-year experience in 57 patients. J Cardiothorac Vasc Anesth 2000; 14 (3): 243-8
85. Bauer M, Koster A, Pasic M, et al. Recombinant hirudin for extended aortic surgery in patients with heparin-induced thrombocytopenia. J Thorac Cardiovasc Surg 1999; 118 (1): 191-2
86. Riess FC, Kormann J, Pötzsch B. Recombinant himdin as anticoagulant during cardiopulmonary bypass. Anesthesiology 2000; 93 (6): 1551-2
87. Koster A, Pasic M, Bauer M, et al. Himdin as anticoagulant for cardiopulmonary bypass: importance of preoperative renal function. Ann Thorac Surg 2000; 69 (1): 37-41
88. Iqbal O, Gerdisch M, DaValle M, et al. Dosage optimization of antithrombin drugs using ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization and percutaneous coronary interventions [abstract]. J Clin Pharmacol 2000; 40 (9): 1064
89. Koster A, Kuppe H, Crystal GJ, et al. Cardiovascular surgery without cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II using anticoagulation with recombinant hirudin. Anesth Analg 2000; 90: 292-9
90. Despotis GJ, Hogue CW, Saleem R, et al. The relationship between hirudin and activated clotting time: implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery. Anesth Analg 2001; 93: 28-32
91. Lewis BE, Grassman ED, Wrona L, et al. Novastan anticoagulation during renal stent implant in a patient with heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997: 8 (1): 54-8
92. Lewis BE, Rangel Y, Fareed J. The first report of successful carotid stent implant using argatroban anticoagulation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome. Angiology 1998; 49: 61-7
93. Matsuo T, Chikahira Y, Yamada T, et al. Effect of synthetic thrombin inhibitor (MD805) as an alternative drug on heparin induced thrombocytopenia during hemodialysis. Thromb Res 1988; 52: 165-71
94. Koide M, Yamamoto S, Matsuo M, et al. Anticoagulation for heparin-induced thrombocytopenia with spontaneous platelet aggregation in a patient requiring haemodialysis. Nephrol Dial Transplant 1995; 10: 2137-40
95. Steuer S, Boogen C, Plum J, et al. Anticoagulation with r-hirudin in a patient with acute renal failure and heparin-induced thrombocytopenia. Nephrol Dial Transplant 1999; 14: 45-7
96. Schneider T, Heuer B, Deller A, et al. Continuous haemofiltration with r-hirudin (lepirudin) as anticoagulant in a patient with heparin-induced thrombocytopenia (HIT II). Wien Klin Wochenschr 2000; 112: 552-5
97. Van Wyk V, Badenhorst PN, Luus HG, et al. A comparison between the use of recombinant hirudin and heparin during hemodialysis. Kidney Int 1995; 48: 1338-43
98. Brady J, Riccio JA, Yumen OH, et al. Plasmapheresis: a therapeutic option in the management of heparin-associated thrombocytopenia with thrombosis. Am J Clin Pathol 1991; 96: 394-7
99. Greinacher A, Liebenhoff U, Kiefel V, et al. Heparin-associated thrombocytopenia: the effect of various intravenous IgG preparations on antibody mediated platelet activation - a possible new indication for high dose IVIg. Thromb Haemost 1994; 71 (5): 641-5
100. Reid T, Alving BM. Himlog therapy for heparin-associated thrombocytopenia and deep venous thrombosis. Am J Hematol 1994; 45: 352-3
101. Bivalirudin Investigators Brochure. Edition number 2001. 26 Oct 2001
102. Walenga JM, Jeske WP, Samama MM, et al. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin Investig Drugs 2002; 11 (3): 397-407
103. Jeske WP, Jay AM, Haas S, et al. Heparin-induced thrombocytopenic potential of GAG and non-GAG based antithrombotic agents. Clin Appl Thromb Hemost 1999; 5 Suppl. 1: S56-62
104. Jeske WP, Walenga JM, Szatkowski E, et al. Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets. Thromb Res 1997; 88 (3): 271-81
105. Haas S, Walenga JM, Jeske WP, et al. Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications. Semin Thromb Hemost 1999; 25 Suppl. 1: 67-75
106. Walenga JM, Lewis BE, Jeske WP, et al. Combined thrombin and platelet inhibition treatment for HIT patients. Hämostaseologie 1999; 19: 128-33
107. Sharouni E, Oakley CM. Outcome pregnancy in women with valve prostheses. Br Heart J 1994; 7: 196-201
108. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000; 160: 191-6
109. Arnaout MS, Kazma H, Khalil A, et al. Is there a safe anticoagulation protocol for pregnant women with prosthetic heart valves? Clin Exp Obstet Gynecol 1998; 25: 101-4
110. Ginsberg JS, Greet I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001; 119 Suppl.: 122-31
111. Aijaz A, Nelson J, Naseer N. Management of heparin allergy in pregnancy. Am J Hematol 2001; 67 (4): 268-9
112. Huhle G, Geberth M, Hoffmann U, et al. Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin. Gynecol Obstet Invest 2000; 49 (1): 67-9